Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
January 2022
2019-EULAR/ACR Classification Criteria Domains at Diagnosis: Predictive Factors of Long-Term Damage In Systemic Lupus Erythematosus
Clin Rheumatol. 2021. Epub ahead of print
Single-centre, retrospective analysis identifying that specific domains in the 2019-EULAR/ACR criteria at diagnosis are associated with long-term organ-specific damage, particularly renal and neuropsychiatric harm.
November 2021
Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial
Ann Intern Med. 2021. Epub ahead of print. doi: 10.7326/M21-2078.
Preliminary evidence suggests that belimumab after rituximab could be developed as a therapeutic strategy for patients with Systemic Lupus Erythematosus (SLE) refractory to conventional therapy.
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Arthritis Rheumatol. 2021;73(10):183–46
Despite evidence of strong pathway inhibition, findings from a Phase 2 study of patients with moderate-to-severe SLE indicate that fenebrutinib did not demonstrate a treatment benefit over placebo.
Keywords:
What Are The Benefits And Harms Of Belimumab For Patients With Systemic Lupus Erythematosus?: A Cochrane Review Summary With Commentary
Int J Rheum Dis. 2021;24(10):1331–3
Biologic therapies, particularly belimumab, show promising results in the clinical management of SLE.
B-cell Depletion With Obinutuzumab for the Treatment of Proliferative Lupus Nephritis: A Randomised, Double-blind, Placebo-controlled Trial
Ann Rheum Dis. 2021. doi:10.1136/annrheumdis-2021-220920
Phase 2 study data support the use of obinutuzumab in proliferative lupus nephritis (LN) being further evaluated in a global Phase 3 study.
October 2021
Long-term Outcome Of A Randomised Controlled Trial Comparing Tacrolimus With Mycophenolate Mofetil As Induction Therapy For Active Lupus Nephritis
Ann Rheum Dis 2020;79:1070–6
Tacrolimus is non inferior to MMF as an induction therapy for LN.
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
N Engl J Med 2020:211–20
Morand et al demonstrate a greater BICLA response at Week 52 for patients treated with anifrolumab versus those treated with placebo.
Keywords:
Two-Year, Randomised, Controlled Trial of Belimumab in Lupus Nephritis
N Engl J Med. 2020;383(12):1117–28.
LN occurs in 25–60% of patients with SLE. However, patients with LN are often excluded from clinical trials of SLE therapies.
A Randomized, Controlled Double-Blind Study Comparing The Efficacy And Safety Of Dose-Ranging Voclosporin With Placebo In Achieving Remission In Patients With Active Lupus Nephritis
Kidney Int 2019;95:219–31
Calcineurin inhibitors have the potential to increase the likelihood of complete renal remission (CRR) when added to standard-of-care induction therapy for LN.
Baricitinib for Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 2018;392:222–31
This international Phase 2 study aimed to assess the efficacy and safety of baricitinib, an oral JAK-1 and -2 inhibitor, in patients with SLE who were not adequately controlled despite standard background therapy.